Prescribing FEIBA

  • Provide rapid onset and sustained activity with FEIBA
  • A dosing interval that helps extend patient freedom1
  • Proven in on-demand therapy:
    • Up to 93% efficacy in bleeding episodes (153/165) in a prospective study2
    • 79% (83/106) of bleeding episodes were controlled within 36 hours of the first infusion4
  • FEIBA prophylaxis shown to reduce bleed frequency and helps preserve joints4-8
    • 78% average reduction in joint bleeds in a meta-analysis of six studies8
    • Early long-term FEIBA prophylaxis could prevent severe arthropathy in a case series of seven pediatric patients on ITI treatment7
    • Benefit with as few as three infusions per week4,5
  • FEIBA is an integral part of inhibitor management3,9
    • Patient responses may vary, so both agents have an important role in inhibitor management
  • FEIBA is trusted and proven
    • Used in more than 60 countries worldwide
    • Used successfully for more than 30 years10

In this section:

  • Indications: Learn about the approved indications for FEIBA
  • Using FEIBA: Learn the recommended dose for each situation and how to reconstitute FEIBA
  • Working with patients: Gain insights into how to manage your haemophilia patients with inhibitors. This section covers:
    • Identifying problem bleeds: Understand why early evaluation of problem bleeds is critical to the management of patients with inhibitors
    • Pain assessment: Learn how VAS scores can improve the overall accuracy of bleed assessment
    • Treatment challenges: Patients with inhibitors present a difficult clinical challenge. Learn how to manage the challenges.
    • Patient resources: Get links to valuable sites that can help patients with inhibitors and caregivers find the information and support they need

Important Safety Information

FEIBA must not be used in the following situations if therapeutic alternatives to FEIBA are available:

  • Hypersensitivity to the product or any of the components.
  • Disseminated Intravascular Coagulation (DIC).
  • Acute thrombosis or embolism (including myocardial infarction).

Thrombotic and thromboembolic events, including disseminated intravascular coagulation (DIC), venous thrombosis, pulmonary embolism, myocardial infarction, and stroke have occurred in the course of treatment with FEIBA, particularly after administration of doses above the maximum daily dose and/or prolonged application or in patients with other risk factors for thromboembolic events.
As with any intravenously administered plasma product, allergic type hypersensitivity reactions may occur; patients should be informed of the early signs of hypersensitivity reactions. When medicines prepared from human blood or plasma are administered, the possibility of passing on infection cannot be totally excluded. This also applies to any unknown or emerging viruses or other types of infections.
Administration of FEIBA to patients with inhibitors may result in an initial anamnestic rise in inhibitor levels. Upon continued administration of FEIBA, inhibitors may decrease over time. Clinical and published data suggest that the efficacy of FEIBA is not reduced.


  1. 1. FEIBA Summary of Product Characteristics 2010.
  2. 2. Hilgartner MW, Knatterud GL. The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in haemophiliacs with inhibitors. Blood. 1983:61:36-40.
  3. 3. Astermark J, Donfield SM, DiMichele DM, Gringeri A, Gilbert SA, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood. 2007;109(2):546-551.
  4. 4. Leissinger CA, Becton DL, Ewing NP, Valentino LA. Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors. Haemophilia. 2007:1-7.
  5. 5. DiMichele D, Négrier C. A retrospective postlicensure survey of FEIBA efficacy and safety. Haemophilia. 2006;12:352-362.
  6. 6. Valentino LA. The benefits of prophylactic treatment with APCC in patients with haemophilia and high-titre inhibitors: a retrospective case series. Haemophilia. 2009: 15:733-742.
  7. 7. Ettingshausen CE, Kreuz W. Early long-term FEIBA prophylaxis in haemophilia A patients with inhibitor after failing immune tolerance induction: A prospective clinical case series. Haemophilia: 2010: 16:90-100.
  8. 8. Valentino LA. Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors. Haemophilia. 2010: 16:263-271.
  9. 9. Berntorp E. Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors. Haemophilia. 2009;15(1):3-10.
  10. 10. Luu H, Ewenstein B. FEIBA safety profile in multiple modes of clinical and home-therapy application. Haemophilia. 2004:10(Suppl. 2):10-16

Rapid onset and sustained activity

FEIBA stops bleeds quickly and offers a long dosing interval. Read more

Proven efficacy

Discover the efficacy of FEIBA in both on-demand and prophylaxis treatment. Read more

Integral to inhibitor management

Learn how FEIBA is integral to the management of patients with inhibitors. Read more


Access articles related to managing haemophilia patients with inhibitors. Read more